Oncology · Phase III

Top sponsors

• AstraZeneca 75 programs
• Chinese Academy of 70 programs
• HOFFMANN-LA ROCHE 68 programs
• MSD Merck Sharp 56 programs
• First People's Hospital 53 programs
• Ningbo Cancer Hospital 44 programs
• United Therapeutics Europe 43 programs
• Anaxis Pharma 37 programs
• AstraZeneca 37 programs
• Novartis India 32 programs
• George Institute for 29 programs
• Takeda 28 programs

1. Telisotuzumab Vedotin, DOCETAXEL

   AbbVie Deutschland GmbH & Co. KG

   c-Met overexpressing EGFR wildtype non-squamous non-small cell lung cancer

   phase 3 · small molecule · active

   1 trial →

2. Thalidomide

   United Therapeutics Europe Ltd

   Prostate Cancer

   phase 3 · small molecule · completed

   1 trial →

3. The placebo tablet composition is: Collodial...

   The George Institute

   Colon and rectal cancer tumor stage II-III, tumor with somatic alterationsin PIK3CA, PIK3R1 or PTEN

   phase 3 · small molecule · active

   1 trial →

4. Tiaoshen Anti-cancer Granules

   The First People's Hospital of Lianyungang

   Ovarian Neoplasms Malignant

   phase 3 · small molecule · active

   1 trial →

5. Tibsovo 250 mg film-coated tablets

   The George Institute

   ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma

   phase 3 · small molecule · active

   1 trial →

6. Tinidazole oral microneedle patch

   The First People's Hospital of Lianyungang

   Evaluate the DFS of Patients With Esophageal Cancer Who Underwent Radical Operation After Regular Removal of Porphyromonas Gingivalis

   phase 3 · other · active

   1 trial →

7. Tiragolumab

   Hoffmann-La Roche

   Esophageal Squamous Cell Carcinoma

   phase 3 · small molecule · active

   1 trial →

8. Tislelizumab

   BeiGene

   Recurrent or Metastatic Nasopharyngeal Cancer

   phase 3 · small molecule · completed

   1 trial →

9. Tislelizumab

   Xiyuan Hospital of China Academy of Chinese Medical Sciences

   Locally Advanced Rectal Carcinoma

   phase 3 · small molecule · active

   1 trial →

10. Tislelizumab

    BeiGene

    Non-small Cell Lung Cancer

    phase 3 · small molecule · completed

    2 trials →

11. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Urothelial Carcinoma

    phase 3 · small molecule · active

    1 trial →

12. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Classical Hodgkin Lymphoma

    phase 3 · small molecule · terminated

    1 trial →

13. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 3 · small molecule · completed

    1 trial →

14. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Non Small Cell Lung Cancer

    phase 3 · small molecule · active

    4 trials →

15. Tislelizumab

    The First People's Hospital of Lianyungang

    Rectal Neoplasms

    phase 3 · small molecule · active

    1 trial →

16. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colonic Neoplasms

    phase 3 · small molecule · active

    1 trial →

17. Tislelizumab + SOX Chemotherapy

    The First People's Hospital of Lianyungang

    Gastric Cancer Stage III

    phase 3 · small molecule · active

    1 trial →

18. Tislelizumab（neoadjuvant）

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinomas

    phase 3 · small molecule · active

    1 trial →

19. Tora-Dol /ml soluzione iniettabile for Patients scheduled for major su…

    Fondazione Telethon ETS

    Patients scheduled for major surgery for oncologic indication

    phase 3 · small molecule · active

    1 trial →

20. Toripalimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non Small Cell Lung Cancer

    phase 3 · small molecule · active

    1 trial →

21. Toripalimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 · small molecule · active

    2 trials →

22. Trabectedin

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    Ovarian Cancer

    phase 3 · small molecule · completed

    1 trial →

23. Trastuzumab

    Hoffmann-La Roche

    Metastatic Breast Cancer

    phase 3 · small molecule · terminated

    1 trial →

24. Trastuzumab

    Mylan IRE Healthcare Limited

    Breast Cancer

    phase 3 · mab · completed

    1 trial →

25. Trastuzumab

    Celltrion Healthcare Australia Pty Ltd

    HER2-positive Carcinoma of Breast

    phase 3 · small molecule · completed

    1 trial →

26. Trastuzumab Deruxtecan

    Daiichi Sankyo

    Gastric Cancer

    phase 3 · small molecule · active

    1 trial →

27. Trastuzumab Deruxtecan

    AstraZeneca

    Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 3 · small molecule · active

    1 trial →

28. Trastuzumab Deruxtecan

    Daiichi Sankyo

    Ovarian Cancer

    phase 3 · small molecule · active

    1 trial →

29. Trastuzumab Deruxtecan

    AstraZeneca

    Breast Neoplasms

    phase 3 · small molecule · active

    1 trial →

30. Trastuzumab Deruxtecan

    Daiichi Sankyo

    Non-small Cell Lung Cancer

    phase 3 · small molecule · active

    1 trial →

31. Trastuzumab Emtansine

    Hoffmann-La Roche

    Metastatic Breast Cancer

    phase 3 · small molecule · terminated

    1 trial →

32. Trastuzumab and neratinib

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    Early-stage Breast Cancer

    phase 3 · small molecule · active

    1 trial →

33. Trastuzumab deruxtecan

    AstraZeneca

    Breast Cancer; HER2-positive; Metastatic

    phase 3 · small molecule · active

    1 trial →

34. Trastuzumab deruxtecan

    AstraZeneca

    Advanced or Metastatic Breast Cancer

    phase 3 · small molecule · active

    1 trial →

35. Trastuzumab emtansine

    Hoffmann-La Roche

    Breast Cancer

    phase 3 · small molecule · completed

    3 trials →

36. Tremelimumab

    AstraZeneca

    Hepatocellular Carcinoma

    phase 3 · small molecule · active

    1 trial →

37. Tropion-Breast05

    AstraZeneca AB

    Triple-negative Breast Cancer

    phase 3 · small molecule · active

    1 trial →

38. Two Anti-angiogenesis Drugs（Endostar and Thalidomide）

    The First People's Hospital of Lianyungang

    Colorectal Neoplasms

    phase 3 · small molecule · active

    1 trial →

39. Tyrosine kinase inhibitor (TKIs)

    The First People's Hospital of Lianyungang

    Philadelphia Chromosome Positive Acute Lymphocytic Leukemia

    phase 3 · small molecule · active

    1 trial →

40. U31402-A-U301

    Daiichi Sankyo

    Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC)

    phase 3 · small molecule · active

    1 trial →

41. UC-0103/1102

    Ningbo Cancer Hospital

    oestrogen-receptor (ER)-positive HER2-negative breast carcinoma

    phase 3 · small molecule · active

    1 trial →

42. UC-0103/1802

    Ningbo Cancer Hospital

    Advanced or metastatic soft tissue sarcoma (STS) in patients ≥65 years old

    phase 3 · small molecule · active

    1 trial →

43. UC-0110/1609

    Ningbo Cancer Hospital

    High-risk stage III colon cancer

    phase 3 · small molecule · active

    1 trial →

44. UC-0140/1615

    Ningbo Cancer Hospital

    ER+/HER2- metastatic breast cancer

    phase 3 · small molecule · active

    1 trial →

45. UC-0140/1901

    Ningbo Cancer Hospital

    Patients with untreated metastatic Estrogen Receptor positive (ER+), Human Epidermal Growth Factor Receptor-2 negative (HER2-) breast cancer with visceral involvement

    phase 3 · small molecule · active

    1 trial →

46. UC-BCG-2409/BIG 2402

    Ningbo Cancer Hospital

    Premenopausal patients with high-risk HR-positive/HER2-negative breast cancer (BC) defined by tumour size and axillary lymph node status. One of the following must apply: a. 1-3 lymph nodes involved AND any invasive tumour size. b. node negative (including micrometastases in at least 1 node [i.e. deposit >0.2-2mm diameter]) AND invasive tumour size ≥ 50mm.

    phase 3 · small molecule · active

    1 trial →

47. UC-BCG-2501

    Ningbo Cancer Hospital

    Patients with HR+ HER2- early breast cancer at intermediate risk of recurrence and eligible for adjuvant chemotherapy

    phase 3 · small molecule · active

    1 trial →

48. UC-GIG-2406

    Ningbo Cancer Hospital

    Patients with hepatocellular carcinoma with high tumor burden.

    phase 3 · small molecule · active

    1 trial →

Frequently asked questions